Literature DB >> 10893657

A new formulation of fenofibrate: suprabioavailable tablets.

J P Guichard1, P Blouquin, Y Qing.   

Abstract

The rationale for, and development of, a new suprabioavailable fenofibrate tablet formulation is described. The new suprabioavailable tablet formulation combines well-established micronisation technology with a new micro-coating process. The new formulation provides more predictable and reliable drug absorption. Owing to the strong relationship between the fenofibrate dissolution performance and its oral bioavailability, equivalent plasma levels of active principal are achieved at a lower dose, with less inter-subject variability and a reduced food effect. The new suprabioavailable tablet may, therefore, be a more efficient and better tolerated formulation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10893657

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  10 in total

Review 1.  Fenofibrate: a review of its use in dyslipidaemia.

Authors:  Kate McKeage; Gillian M Keating
Journal:  Drugs       Date:  2011-10-01       Impact factor: 9.546

Review 2.  Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.

Authors:  Gillian M Keating; Douglas Ormrod
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  Ethyl 2-[4-(4-chloro-benzo-yl)phen-oxy]-2-methyl-propano-ate.

Authors:  Zhao Yang; Zhi-Xiang Wang
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-05-16

4.  In situ formation of nanocrystals from a self-microemulsifying drug delivery system to enhance oral bioavailability of fenofibrate.

Authors:  You-Meei Lin; Jui-Yu Wu; Ying-Chen Chen; Yu-Der Su; Wen-Tin Ke; Hsiu-O Ho; Ming-Thau Sheu
Journal:  Int J Nanomedicine       Date:  2011-10-19

5.  Methyl 2-[4-(4-chloro-benzo-yl)phen-oxy]-2-methyl-propano-ate.

Authors:  Baohua Zou; Zheng Fang; Hui Zhong; Kai Guo; Ping Wei
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-05-12

Review 6.  A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations.

Authors:  Hua Ling; John T Luoma; Daniel Hilleman
Journal:  Cardiol Res       Date:  2013-05-09

Review 7.  Type 2 Diabetes Complicated With Heart Failure: Research on Therapeutic Mechanism and Potential Drug Development Based on Insulin Signaling Pathway.

Authors:  Hui Ye; Yanan He; Chuan Zheng; Fang Wang; Ming Yang; Junzhi Lin; Runchun Xu; Dingkun Zhang
Journal:  Front Pharmacol       Date:  2022-03-03       Impact factor: 5.810

Review 8.  Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review.

Authors:  Konstantinos Tziomalos; Vasilios G Athyros
Journal:  Int J Nanomedicine       Date:  2006

9.  Aminoclay-lipid hybrid composite as a novel drug carrier of fenofibrate for the enhancement of drug release and oral absorption.

Authors:  Liang Yang; Yating Shao; Hyo-Kyung Han
Journal:  Int J Nanomedicine       Date:  2016-03-15

10.  The Influence of Fed State Lipolysis Inhibition on the Intraluminal Behaviour and Absorption of Fenofibrate from a Lipid-Based Formulation.

Authors:  Marlies Braeckmans; Joachim Brouwers; Danny Riethorst; Cécile Servais; Jan Tack; Patrick Augustijns
Journal:  Pharmaceutics       Date:  2022-01-04       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.